ES2547145T3 - Regímenes de dosificación para el tratamiento de enfermedad vascular ocular - Google Patents

Regímenes de dosificación para el tratamiento de enfermedad vascular ocular Download PDF

Info

Publication number
ES2547145T3
ES2547145T3 ES11779606.0T ES11779606T ES2547145T3 ES 2547145 T3 ES2547145 T3 ES 2547145T3 ES 11779606 T ES11779606 T ES 11779606T ES 2547145 T3 ES2547145 T3 ES 2547145T3
Authority
ES
Spain
Prior art keywords
yloxy
pyrimidin
amide
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11779606.0T
Other languages
English (en)
Spanish (es)
Inventor
Mitchell Brigell
Peter End
Vinayak Hosagrahara
Bruce Jaffee
Erik Meredith
Ronald Newton
Stephen Poor
Yubin Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2547145T3 publication Critical patent/ES2547145T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES11779606.0T 2010-10-27 2011-10-25 Regímenes de dosificación para el tratamiento de enfermedad vascular ocular Active ES2547145T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40721810P 2010-10-27 2010-10-27
US407218P 2010-10-27
PCT/EP2011/068682 WO2012055884A1 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Publications (1)

Publication Number Publication Date
ES2547145T3 true ES2547145T3 (es) 2015-10-02

Family

ID=44913251

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11779606.0T Active ES2547145T3 (es) 2010-10-27 2011-10-25 Regímenes de dosificación para el tratamiento de enfermedad vascular ocular

Country Status (12)

Country Link
US (1) US20130197016A1 (https=)
EP (1) EP2632458B1 (https=)
JP (1) JP5934229B2 (https=)
KR (1) KR20140008303A (https=)
CN (1) CN103167873A (https=)
AU (1) AU2011322597B2 (https=)
BR (1) BR112013009701A2 (https=)
CA (1) CA2814439A1 (https=)
EA (1) EA022873B1 (https=)
ES (1) ES2547145T3 (https=)
MX (1) MX2013004782A (https=)
WO (1) WO2012055884A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
JP6669499B2 (ja) * 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US10174006B2 (en) * 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
CN105917270A (zh) 2013-11-15 2016-08-31 视觉力学有限责任公司 具有亲水层的接触透镜
JPWO2015147204A1 (ja) * 2014-03-27 2017-04-13 国立大学法人京都大学 血管新生増殖因子を阻害する医薬組成物
JP6774947B2 (ja) 2014-12-09 2020-10-28 タンジブル サイエンス インコーポレイテッド 生体適合性層を有する医療デバイスコーティング
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1652847B1 (en) 2001-04-27 2008-05-28 Kirin Pharma Kabushiki Kaisha Quinoline and quinazoline derivatives for the treatment of tumors
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
PL1954281T3 (pl) 2005-11-29 2011-07-29 Novartis Ag Sposób leczenia raka
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Also Published As

Publication number Publication date
JP2013540791A (ja) 2013-11-07
KR20140008303A (ko) 2014-01-21
CA2814439A1 (en) 2012-05-03
EP2632458B1 (en) 2015-08-12
EA022873B1 (ru) 2016-03-31
US20130197016A1 (en) 2013-08-01
BR112013009701A2 (pt) 2016-07-19
AU2011322597A1 (en) 2013-05-02
WO2012055884A1 (en) 2012-05-03
JP5934229B2 (ja) 2016-06-15
MX2013004782A (es) 2013-06-03
AU2011322597B2 (en) 2015-09-10
EP2632458A1 (en) 2013-09-04
EA201390618A1 (ru) 2013-08-30
CN103167873A (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
ES2547145T3 (es) Regímenes de dosificación para el tratamiento de enfermedad vascular ocular
ES2912105T3 (es) Composición medicinal que comprende tivozanib.
ES2627944T3 (es) Composiciones y métodos de tratamiento de hipertensión pulmonar
KR102906248B1 (ko) 익상편을 치료하기 위한 조성물 및 방법
ES2370751T3 (es) Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
ES2763556T3 (es) Antagonistas fluorados de integrina
US20130012531A1 (en) Treatment method
CN115768419A (zh) 用于色满卡林前药治疗的改进方法和组合物
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
TW200815416A (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
TW200914014A (en) Pharmacological adjunctive treatment associated with glaucoma filtration surgery
CN118119390A (zh) 用于延长释放克罗卡林疗法的组合物和方法
US20080096859A1 (en) Compositions and Methods for Treating Ophthalmic Diseases
US10174006B2 (en) Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
ES2239042T3 (es) Nueva combinacion para el tratamiento de la disfuncion sexual.
JP2019534269A5 (https=)
WO2018069893A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
ES2291641T3 (es) Uso farmaceutico de inhibidores de cox-2 en trastornos oculares mediados por angiogenesis.
ES2285088T3 (es) Composiciones farmaceuticas de liberacion modificada.
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
US20160095861A1 (en) Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases
JP2006188496A (ja) ｐ３８ＭＡＰキナーゼ阻害剤を有効成分とする掻痒治療剤